ENTBF.US Entheon Biomedical Corp
- Market cap
- USD 832K
- P/E
- 6.0x
- P/B
- 2.45x
- ROE
- -100.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Mar 2026.
Is ENTBF.US undervalued?
Graham numberENTBF.US trades 19.1% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Entheon Biomedical Corp fundamental analysis
No fundamental analysis for Entheon Biomedical Corp yet.
Entheon Biomedical Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Entheon Biomedical Corp
Entheon Biomedical Corp. operates as a biotechnology research and development company. It develops products for treating addiction and substance use disorders. Entheon Biomedical Corp. is headquartered in Vancouver, Canada.
Full company profileEntheon Biomedical Corp financial statements
Entheon Biomedical Corp annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 21.7K | 190K | 250K | 0.00 | 0.00 |
| Gross Profit | - | - | - | 0.00 | 9.13K | - | 250K | 0.00 | 0.00 |
| Operating Income | -118K | -170K | -145K | -4.38M | -9.11M | -3.60M | -313K | -333K | -334K |
| EBITDA | -181K | -230K | -147K | -4.37M | -8.62M | -3.60M | -313K | -333K | -334K |
| Net Income | -145K | -158K | -147K | -4.38M | -8.89M | -8.52M | -300K | -318K | -324K |
| EPS | -0.04 | -0.03 | -0.02 | -0.11 | -0.15 | -0.14 | -0.05 | -0.04 | -0.02 |
| Balance Sheet | |||||||||
| Total Assets | 559K | 1.84M | 1.72M | 4.47M | 9.98M | 769K | 401K | 185K | 354K |
| Total Liabilities | 185K | 39.0K | 28.0K | 728K | 928K | 155K | 85.3K | 39.8K | 29.8K |
| Shareholders' Equity | 374K | 1.80M | 1.69M | 3.74M | 9.05M | 615K | 316K | 145K | 324K |
| Cash & Short-term Investments | 344K | 1.22M | 1.13M | 2.79M | 2.05M | 680K | 345K | 136K | 322K |
| Cash Flow | |||||||||
| Operating Cash Flow | -67.5K | -221K | -473K | -2.84M | -1.98M | -1.98M | -360K | -356K | -315K |
| Capital Expenditure | 163K | 411K | 9.03K | 9.03K | 98.0K | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -231K | -633K | -187K | -2.85M | -5.71M | -1.95M | -360K | -356K | -315K |
| Ratios | |||||||||
| ROE | -38.8% | -8.7% | -8.7% | -117.0% | -98.2% | -1,386.4% | -95.0% | -218.8% | -100.0% |
| ROA | -25.9% | -8.5% | -8.5% | -98.0% | -89.1% | -1,107.7% | -74.8% | -171.7% | -91.6% |
| Net Profit Margin | - | - | - | - | -41,008.6% | -4,492.2% | -119.8% | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Entheon Biomedical Corp dividends
Entheon Biomedical Corp has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Mar 1, 2024.
Who owns Entheon Biomedical Corp
- Insiders 4.82%
- Institutions 0.00%
- Public & others 95.18%
- Shares outstanding 13.9M
- Free float 13.1M
Entheon Biomedical Corp company profile
- Company name
- Entheon Biomedical Corp
- Ticker
- ENTBF.US
- ISIN
- CA29383X2023
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1
- Fiscal year end
- March
- Address
- 999 West Broadway, Vancouver, BC, Canada, V5Z 1K5
- Phone
- 604-562-3932
- Website
- entheonbiomedical.com
About Entheon Biomedical Corp
Entheon Biomedical Corp. operates as a biotechnology research and development company. It develops products for treating addiction and substance use disorders. Entheon Biomedical Corp. is headquartered in Vancouver, Canada.
Entheon Biomedical Corp management
3- Mr. Timothy KoPresident, CEO, Corporate Secretary & Director · born 1986
- Mr. Soo-Whan KimInterim Chief Financial Officer
- Dr. Brian E. Jahns Pharm.D.Chief Business Officer